FDA Strengthens Hepatitis B Warning on Two Cancer Drugs

The FDA has upped its warnings on two cancer drugs: GlaxoSmithKline’s Arzerra and Roche and Biogen Idec’s Rituxan. The agency says that the two may cause the hepatitis B virus to reactivate in carriers.
Reuters